Dr. Mary Claire Haver's Menopause Protocol: The Private-Clinic Pathway She Likely Used

Who Is Dr. Mary Claire Haver and Why Does Her Protocol Matter?

Dr. Mary Claire Haver is a board-certified OB-GYN, a certified menopause practitioner through The Menopause Society, and the author of the New York Times bestseller "The New Menopause." She is also, by her own public account, a woman who has lived through perimenopause and made deliberate clinical choices about how to manage it. That combination, clinician plus patient, gives her a platform that has reached millions of women who feel dismissed by conventional medicine.

Her work matters for a specific reason. Women in their 40s and 50s have historically received fragmented, fear-based guidance about hormone therapy, shaped in large part by a misreading of the Women's Health Initiative data from 2002. Dr. Haver, along with a growing cohort of menopause specialists, has spent years explaining what that trial actually showed, what it did not show, and why its conclusions were applied too broadly to younger, healthier women.

This article is a clinical reconstruction, not a biography. The goal is to answer the question women keep asking: if Dr. Haver had access to the best menopause care available, what would that care look like, and how do you get the same?

The Clinical Starting Point: How a Menopause Specialist Evaluates You

A private menopause clinic visit is not a 7-minute appointment. It typically runs 45 to 90 minutes and produces a clinical picture built from several data streams.

Hormone Panel Interpretation

Menopause is technically a retrospective diagnosis, defined as 12 consecutive months without a menstrual period. But perimenopause, the transition that may last 4 to 10 years before that final period, is the phase when most women feel the worst and receive the least help.

FSH above 25 IU/L, combined with symptoms, suggests the ovaries are beginning to fail. Estradiol levels fluctuate wildly in perimenopause, so a single low reading means less than the symptom pattern. Specialists like Dr. Haver use labs as context, not as gatekeepers. The 2023 Menopause Society Position Statement supports initiating HRT based on clinical presentation in symptomatic perimenopausal women even when labs are ambiguous.

Cardiometabolic and Bone Baseline

A thorough private-clinic intake also includes fasting lipids, fasting glucose, HbA1c, thyroid panel, and a DEXA scan or Fracture Risk Assessment (FRAX) score. Estrogen loss accelerates bone resorption, and women can lose up to 20% of their bone density in the five to seven years following menopause. Getting a baseline DEXA early in the transition is a clinical priority that general practice frequently skips.

Body Composition Assessment

Standard BMI is a poor proxy for metabolic health in menopausal women. Estrogen decline drives visceral fat redistribution, and a woman who was lean during her reproductive years may accumulate abdominal adiposity rapidly after her final period. A private clinic may use DEXA-derived body composition, bioelectrical impedance, or waist-to-hip ratio alongside BMI.

The Hormone Therapy Protocol Dr. Haver Describes

Dr. Haver has been explicit in podcasts, interviews, and her book about what she takes and why. The protocol she describes is squarely within current evidence-based guidelines.

Transdermal Estradiol: The Delivery Route That Changes the Risk Profile

The most clinically significant detail in her approach is the delivery route: transdermal, not oral. Transdermal estradiol (patches, gels, or sprays) bypasses first-pass hepatic metabolism. This means it does not raise clotting factors in the same way oral estrogen does, a pharmacokinetic difference with real consequences.

A large observational study published in BMJ found that transdermal estradiol was not associated with increased venous thromboembolism risk, while oral estrogen was. A 2019 study in the BMJ confirmed that transdermal estradiol carried no measurable increase in stroke risk. For a woman with cardiovascular risk factors, migraine with aura, or a personal or family history of clotting disorders, transdermal delivery is not just a preference; it is the safer choice.

Typical doses used in clinical practice range from 0.025 mg to 0.1 mg per day via patch, or 0.5 g to 1.5 g of estradiol gel. Dose titration over 8 to 12 weeks is standard, guided by symptom response rather than serum levels alone.

Micronized Progesterone: Body-Identical, Not Synthetic

Any woman who has a uterus requires progestogen alongside estrogen to protect the endometrium from hyperplasia and cancer. The choice of progestogen matters.

The E3N cohort study and subsequent analyses found that micronized progesterone (Prometrium, Utrogestan) was associated with a lower breast cancer risk than synthetic progestins such as medroxyprogesterone acetate (MPA). The WHI used MPA, which is one reason its breast cancer finding does not translate directly to modern body-identical regimens.

Micronized progesterone is dosed at 100 mg nightly for continuous use, or 200 mg for 12 days per cycle in a sequential regimen. It has a mild sedative effect via GABA-A receptor activity, which many women find beneficial for the sleep disruption that is one of the most debilitating symptoms of perimenopause.

Testosterone: The Hormone No One Is Talking About Enough

Dr. Haver has been vocal about testosterone's role in women's health, and this is an area where the clinical conversation has lagged badly behind the evidence. Women produce testosterone in the ovaries and adrenal glands, and levels decline through the reproductive years, dropping sharply after surgical menopause.

A 2019 global consensus statement on testosterone therapy in women concluded that testosterone supplementation improves sexual function, specifically hypoactive sexual desire disorder (HSDD), in postmenopausal women. The authors explicitly noted the absence of approved female testosterone formulations in most countries as a systemic failure.

In clinical practice, women are typically prescribed compounded testosterone cream or gel at doses of 0.5 mg to 2 mg per day (far below male doses), or male-formulation gel at a fraction of the male dose. Monitoring free and total testosterone, and SHBG, every 3 to 6 months during initiation is standard.

The WomanRx Three-Tier Hormone Framework for Menopause:

| Tier | Hormone | Route | Primary Benefit | Who Needs It | |------|---------|-------|-----------------|--------------| | 1 | Estradiol | Transdermal | Vasomotor symptoms, bone, cardiovascular, cognition | All symptomatic women without contraindications | | 2 | Progesterone | Oral micronized | Endometrial protection, sleep | Women with intact uterus | | 3 | Testosterone | Topical compounded | Libido, energy, cognition, body composition | Women with HSDD or androgen insufficiency symptoms |

Pregnancy, Lactation, and Contraception: What Every Perimenopausal Woman Must Know

This section is required reading if you are in perimenopause and not yet at your final menstrual period.

Hormone therapy is contraindicated in confirmed pregnancy. Estrogen and progesterone products used for menopause management are not the same as medications used to support pregnancy, and they are not appropriate during gestation.

The critical point that is frequently missed: perimenopausal women can still ovulate, even irregularly, and can still conceive. The ACOG Committee Opinion on Contraception in Midlife Women notes that unintended pregnancy rates in women aged 40 to 44 are higher than in adolescents in some populations, largely because contraception is abandoned prematurely.

A woman who is perimenopausal and sexually active with a male partner needs contraception until she has been amenorrheic for 12 consecutive months (post-menopause) or until age 55, whichever comes first, per FSRH guidance.

Options that work alongside HRT:

• Low-dose combined oral contraceptive pill (can also manage perimenopausal symptoms, but carries higher VTE risk than HRT)
• Progestogen-only pill
• Hormonal IUD (Mirena also provides endometrial protection, allowing estrogen-only HRT)
• Condoms (no systemic hormone interaction)

Lactation: Standard menopause HRT is not indicated during breastfeeding. Postpartum women experiencing surgically or medically induced menopause require specialist input.

The Lifestyle Protocol: What Dr. Haver Says Is Non-Negotiable

Dr. Haver is consistent on several lifestyle interventions that she frames not as adjuncts but as treatments in their own right.

Protein and the Muscle Mass Crisis

Estrogen has anabolic effects on skeletal muscle. As it declines, women experience accelerated sarcopenia. A 2021 review in Nutrients found that postmenopausal women require higher protein intakes than premenopausal women to maintain muscle mass, with evidence supporting 1.2 to 1.6 g per kilogram of body weight per day.

Dr. Haver targets approximately 1 gram of protein per pound of body weight, distributed across meals to maximize muscle protein synthesis. Leucine-rich sources (eggs, meat, fish, legumes) are prioritized. This is not a fad. The mechanistic case for protein adequacy in postmenopausal women is solid.

Resistance Training: The One Intervention With No Downside

ACOG guidelines support resistance exercise for women across the lifespan, and the bone and muscle benefits in postmenopausal women are well-documented. A meta-analysis in Osteoporosis International found that resistance training significantly improved bone mineral density at the lumbar spine and femoral neck in postmenopausal women, with effect sizes comparable to bisphosphonate therapy in some subgroups.

Dr. Haver recommends 3 to 4 sessions per week, emphasizing compound movements: squats, deadlifts, rows, presses. She is specific about load: the weight needs to be heavy enough to challenge the muscle, not the light-weights, high-reps approach that dominated women's fitness for decades.

Creatine: The Supplement With Actual Data in Women

Creatine monohydrate is one of the best-studied supplements in existence, and women remain under-represented in the research. A 2021 review in Nutrients noted that women may respond differently to creatine than men due to hormonal influences on creatine synthesis, and that postmenopausal women specifically may derive greater relative benefit.

A dose of 3 to 5 g per day is standard. Potential benefits include improved muscle strength, bone density support, and emerging data on cognitive function. A 2022 randomized controlled trial found that postmenopausal women taking creatine with resistance training had significantly better muscle strength gains than those doing resistance training alone.

Sleep Architecture and Why It Requires Active Management

Sleep disruption in perimenopause and menopause is not simply a symptom to tolerate. Research published in Menopause found that sleep disturbance in menopausal women is associated with increased cardiometabolic risk independent of other factors. Progesterone's sedative effect is one reason it is typically dosed at night. Dr. Haver also emphasizes sleep hygiene, including consistent sleep and wake times, limiting alcohol (a significant but frequently minimized trigger for night sweats), and managing blue-light exposure.

Conditions That Change the Picture: PCOS, Thyroid, and Surgical Menopause

PCOS Into Menopause

Women with PCOS do not simply "age out" of the condition at menopause. The metabolic features, insulin resistance, dyslipidemia, elevated cardiovascular risk, persist and may worsen. Research published in Fertility and Sterility confirms that women with PCOS entering menopause have a different hormonal profile than women without PCOS, with testosterone declining more slowly and the transition sometimes appearing less symptomatic on the surface while cardiometabolic risk remains elevated. A menopause specialist familiar with PCOS history will adjust the monitoring and possibly the hormone regimen accordingly.

Thyroid Disease and Menopause Overlap

Postpartum thyroiditis affects approximately 5 to 10% of women after delivery, and thyroid autoimmunity increases around menopause. Hypothyroidism symptoms, fatigue, weight gain, brain fog, cold intolerance, overlap substantially with menopause symptoms. A private clinic intake always includes a full thyroid panel: TSH, free T4, and ideally TPO antibodies. Treating thyroid disease and menopause simultaneously is not unusual, and the two conditions interact: estrogen raises thyroxine-binding globulin, meaning oral estrogen increases levothyroxine requirements in hypothyroid women. Transdermal estradiol has a smaller effect on TBG.

Surgical Menopause: A Different and More Urgent Timeline

Women who undergo bilateral oophorectomy before natural menopause experience an abrupt estrogen withdrawal that carries a significantly higher long-term health burden than natural menopause. A landmark study in Mayo Clinic Proceedings found that women who underwent bilateral oophorectomy before age 45 and did not receive estrogen therapy had significantly increased risks of cognitive impairment, cardiovascular disease, and all-cause mortality. For these women, HRT is not a lifestyle choice; it is replacement of a hormone the body has abruptly lost.

What a Private Menopause Clinic Pathway Actually Looks Like

Not every woman has access to a physician like Dr. Haver, but understanding the care pathway helps you advocate for yourself wherever you receive care.

Initial Consultation (Visit 1)

A thorough history covering menstrual pattern changes, symptom timeline, contraceptive history, family history of breast cancer, heart disease, osteoporosis, stroke, and clotting disorders. Labs ordered: FSH, LH, estradiol, testosterone (total and free), SHBG, TSH, free T4, fasting lipid panel, HbA1c, CBC, CMP. DEXA scan referral placed if patient is within 2 years of her final period or has risk factors.

Treatment Initiation (2 to 4 Weeks Post-Labs)

Prescription of transdermal estradiol (patch or gel) at a conservative starting dose, micronized progesterone if uterus is intact, and a discussion about testosterone. Written medication guide provided. Contraception plan confirmed if not definitively post-menopause.

First Follow-Up (8 to 12 Weeks)

Symptom review using a validated tool such as the Menopause Rating Scale. Dose adjustment if vasomotor symptoms are not controlled. Labs repeated if testosterone was initiated. Blood pressure and weight recorded.

Ongoing Monitoring (Every 6 to 12 Months)

Annual breast exam, mammogram per screening schedule, pelvic exam. Lipid panel and HbA1c annually. Repeat DEXA every 2 years in women with osteopenia, every 1 to 2 years in women on long-term HRT with baseline bone concerns. Testosterone levels every 6 months during the first year of therapy.

Who This Pathway Is Right For, and Who Should Approach It Differently

Strong Candidates for the Full Protocol

Women aged 40 to 60 with vasomotor symptoms (hot flashes, night sweats), sleep disruption, mood changes, cognitive symptoms, genitourinary syndrome of menopause (GSM), decreased libido, or accelerating bone loss. Women with premature ovarian insufficiency (POI) diagnosed before age 40. Women with surgical menopause at any age.

Women Who Need a Modified Approach

Women with a personal history of estrogen-receptor-positive breast cancer should discuss HRT with their oncologist. The data on HRT safety after breast cancer is genuinely contested. A 2019 randomized trial in The Lancet found increased breast cancer recurrence in survivors using local or systemic HRT versus placebo, though other observational data present a more nuanced picture. This is not a category where a single answer fits every woman.

Women with active liver disease should avoid oral estrogen. Women with a history of DVT or PE should use transdermal estrogen only and require hematology input. Women with undiagnosed vaginal bleeding need evaluation before starting HRT.

Women in the Reproductive Years

If you are 35 to 44 and experiencing perimenopausal symptoms, you deserve the same thorough evaluation. Perimenopause can begin up to a decade before the final menstrual period, and symptoms in this stage are frequently attributed to anxiety, depression, or burnout. Hormone testing combined with symptom assessment, not labs alone, is the right standard.

The Evidence Gap: What We Do Not Yet Know

Women have been under-represented in clinical trials for decades. The WHI enrolled women with a mean age of 63, well past the window where most menopause specialists now consider HRT most beneficial. Long-term RCT data on testosterone therapy in women are thin. The ideal duration of HRT, the optimal monitoring interval for DEXA in women on estrogen, and the cardiometabolic effects of testosterone in postmenopausal women are all areas where clinical practice runs ahead of the trial evidence. Dr. Haver has been candid about this in her writing, and it is a reason she frames lifestyle interventions as co-treatments rather than afterthoughts. The resistance training and protein data in postmenopausal women are actually better powered than some of the hormone data.

The Menopause Society states explicitly that for women under 60 or within 10 years of menopause onset, the benefits of HRT in treating vasomotor symptoms and preventing bone loss outweigh the risks for most women without contraindications. That is the statement that anchors Dr. Haver's approach, and it is the statement you can take to your own clinician.